Presentation is loading. Please wait.

Presentation is loading. Please wait.

Update on CBER HIV-1 Subtype panel

Published byMaria Cameron Modified over 5 years ago

Similar presentations

Presentation on theme: "Update on CBER HIV-1 Subtype panel"— Presentation transcript:

1 Update on CBER HIV-1 Subtype panel
Indira Hewlett, Ph.D CBER/FDA

2 CBER HIV-1 subtype panel
20 specimens representing subtypes A-G of group M, N and O 2 isolates of each subtype of group M, 1 of group N and 5 of group O Dilutions 104, 103, 102 per ml for all subtypes Samples tested by five manufacturers

3 Virus isolates for HIV-1 subtype panel

4 Prototype Panel Composition
Each panel was comprised of 2 isolates Seven members including one negative control per panel; Panel O has nineteen members containing five distinct isolates and four negative controls. Diluted to targeted ranges of Log 2 to Log 4 (copies/ml). Tested by 5 different manufacturer’s assays

5 Multi-lab testing

6 Consensus Values of subtype panel samples

7 Expected final formulation for panel
One isolate of each subtype representing subtypes A-G of group M, N and O Four members including one negative control per panel Diluted to targeted ranges of Log 2 to Log 4 (copies/ml).

8 Summary CBER has developed a well characterized panel for qualitative and quantitative detection of HIV-1 subtype RNA Panel may be used 1) to establish LOD and 2) for lot release of HIV NAT assays for blood and plasma donor screening

9 West Nile virus lot release and validation panel development

10 Background The 2002 US outbreak of WNV identified transmission by Blood transfusion, Transplantation, Breast-feeding, Transplacental and Occupational by percutaneus injury During Aug 28, 2002-March 1, 2003, 61 possible Transfusion-Transmitted cases reported 21 confirmed from 14 blood donations 19 are not transfusion related, 21 inconclusive due to incomplete donor follow-up

11 WNV testing All reported cases of WNV transmission by blood transfusion have occurred during the acute, viremic phase NAT may be the most appropriate strategy to interdict infectious donations Virus titer in blood is low compared to other transmissible viruses (~1-5x103 copies/ml) and the viremia is transient. Impact of pooling on sensitivity of WNV NAT assays is of concern

12 Analytical sensitivity
FDA’s current standard for WNV NAT assays is 100 copies/ml for the individual donation Standard may be revised as assay sensitivity improves and additional data on viremia and infectivity become available in future studies

13 FDA Panel Development Efforts
Lot release panel for licensure and post-market surveillance of NAT tests Qualification panel for evaluation of relative sensitivities of investigational NAT assays

14 FDA NAT Panels FDA NY99 and FDA-Hu2002 isolates characterized by genetic sequencing Viral infectivity determination PFU determined at both FDA and NY Dept. of Health Laboratories, and by cytopathic assays at FDA RNA concentration measurements Fluorescence and Optical density determination TaqMan Final panel specifications are being established through collaborative studies

15 PFU Results on FDA Isolates
At FDA NY99 (CDC Flamingo Isolate) 108/mL HuWNV /mL At NY State Dept. of Health NY99 (CDC Flamingo Isolate) 5.5 x107/mL HuWNV x106/mL

16 Quantitation of virus isolates: copies/mL
Sample Lab 1 Lab 2 Lab 3 Lab 4 Average HuWNV 10-1 109 HuWNV 10-4 106 ND HuWNV 10-7 102 HuWNV oC/2hr 107 NY NY NY NY oC/2hr 108 104 106.5

17 Correlation between Copy/mL and PFU/mL
Sample Av. copy PFU HuWNV 1010 107/mL HuWNV 60oC/2 hr 107 NY99 108/mL NY99 60oC/2 hr 106.5

18 FDA Plan for Qualification Panel
At least 100 pedigreed clinical specimens RNA positive only IgM positive only Dual RNA and IgM positive Panel will be evaluated in collaborative studies using various candidate NAT assays Specifications for NAT panel will be established based on results of collaborative studies

19 Summary Both NY99 and FDA-Hu2002 stocks have a viral titer of 1010 copies/mL PFU titers determined at NY State Dept of Health Laboratory and at FDA were three logs lower than copy numbers Heat treatment of virus resulted in loss of infectivity and 2 to 3 log reduction in copy numbers as determined by TaqMan Prototype panel is being formulated to evaluate performance of panel in a larger collaborative study

20 Acknowledgements Owen Wood Sherwin Lee Nelson Michael, DoD
CBER Owen Wood Sherwin Lee Nelson Michael, DoD Rolf Taffs Harvey Holmes, NIBSC Jinjie Hu Ana Machuca Robert Lanciotti, CDC Maria Rios Laura Kramer, NYDOH

21 Acknowledgements

Download ppt "Update on CBER HIV-1 Subtype panel"

Similar presentations

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Nick Curry, MD, MPH Infectious Diseases Prevention Section
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
Development of an HIV-2 RNA International Standard Harvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group.

Development of an HIV-2 RNA International Standard Harvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.
Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.

Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.
Dengue Virus and Its Risk to the U.S. Blood Supply

Dengue Virus and Its Risk to the U.S. Blood Supply
HIV Testing CDC power point edited by M. Myers

HIV Testing CDC power point edited by M. Myers
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.

Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.

R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.
TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;

TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.

E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.

PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
Update on CBER HIV NAT panels and International panels Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology DETTD/OBRR/FDA May 28, 2009 XXI SoGAT meeting.

Update on CBER HIV NAT panels and International panels Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology DETTD/OBRR/FDA May 28, 2009 XXI SoGAT meeting.
Xenotropic Murine Leukemia Virus Related Virus (XMRV) Informational Presentation BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of.

Xenotropic Murine Leukemia Virus Related Virus (XMRV) Informational Presentation BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of.

Similar presentations

Ads by Google